Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
Özden Hatırnaz Ng,
Ahmet Emre Eşkazan
Affiliations
Özden Hatırnaz Ng
Department of Medical Biology, School of Medicine, Acıbadem University, Istanbul, Turkey
Ahmet Emre Eşkazan
Department of Internal Medicine, Division of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Turkey; Corresponding author.
